<?xml version="1.0" encoding="UTF-8"?>
<p>At present, measles vaccination of humans provides at least partial protection against a potential human-adapted CDV gaining hold in the population, as morbilliviruses are monoserotypic and antibody induced to one member has a degree of cross-neutralization [
 <xref rid="B3-viruses-11-00944" ref-type="bibr">3</xref>]. Measles vaccine has been successfully used in dogs to protect against CDV infection [
 <xref rid="B92-viruses-11-00944" ref-type="bibr">92</xref>,
 <xref rid="B93-viruses-11-00944" ref-type="bibr">93</xref>]. However for humans a more CDV-specific vaccine may be required, as this measles vaccine has been shown to give only partial protection in an experimental CDV primate model [
 <xref rid="B94-viruses-11-00944" ref-type="bibr">94</xref>].
</p>
